Endothelial cell-derived interleukin-6 regulates tumor growth

Area of Science:

• Oncology
• Cell Biology
• Cancer Research

Background:

• Endothelial cells are crucial in cancer, supporting tumor growth beyond angiogenesis.
• Tumor-associated endothelial cells secrete factors enhancing tumor cell survival and stem cell self-renewal.
• Disrupting endothelial cell signaling may inhibit tumor progression.

Purpose of the Study:

• To investigate the role of endothelial-derived IL-6 in tumor cell signaling and growth.
• To determine if silencing IL-6 in endothelial cells impacts tumor development.

Main Methods:

• Primary human dermal microvascular endothelial cells (HDMEC) were engineered to silence IL-6.
• Conditioned medium from these cells assessed IL-6's effect on tumor cell signaling pathways.
• Co-transplantation of modified endothelial cells and tumor cells into mice evaluated tumor growth and angiogenesis.

Main Results:

• Tumor cells near blood vessels exhibited STAT3 phosphorylation, a marker of tumor progression.
• Silencing IL-6 in endothelial cells reduced STAT3 phosphorylation in tumor cells.
• Tumors with IL-6-silenced endothelial cells showed reduced microvessel density, proliferation, and growth.

Conclusions:

• Endothelial cell-derived IL-6 promotes tumor growth by activating STAT3 signaling.
• Targeting endothelial cell signaling pathways, specifically IL-6, could be a therapeutic strategy for cancer patients.